Austin Health

Title
Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group.
Publication Date
2020-11-05
Author(s)
Fakhouri, Fadi
Scully, Marie
Provôt, François
Blasco, Miquel
Coppo, Paul
Noris, Marina
Paizis, Kathy
Kavanagh, David
Pene, Frederic
Quezada, Sol
Hertig, Alexandre
Kissling, Sébastien
O'Brien, Patrick
Delmas, Yahsou
Alberio, Lorenzo
Winer, Norbert
Veyradier, Agnès
Cataland, Spero R
Fremeaux-Bacchi, Veronique
Loirat, Chantal
Remuzzi, Giuseppe
Tsatsaris, Vassilis
Type of document
Journal Article
DOI
10.1182/blood.2020005221
Abstract
Pregnancy and postpartum are high-risk periods for different forms of thrombotic microangiopathy (TMA). However, the management of pregnancy-associated TMA remains ill-defined. This report by an international multidisciplinary (obstetricians, nephrologists, hematologists, intensivists, neonatologists and complement biologists) working group summarizes the current knowledge of these potentially severe disorders and proposes a practical clinical approach to diagnose and manage an episode of pregnancy-associated TMA. This approach takes into account the timing of TMA in pregnancy or postpartum, co-existing symptoms, first-line laboratory work-up and probability-based assessment of possible causes of pregnancy-associated TMA. Its aims are to urgently rule in or out thrombotic thrombocytopenic purpura (TTP) with ADAMTS13 activity testing, to consider alternative disorders with features of TMA (preeclampsia/eclampsia, Hemolysis Elevated Liver enzymes Low Platelets (HELLP) syndrome, antiphospholipid syndrome (APS)) or ultimately to diagnose complement-mediated atypical hemolytic uremic syndrome (aHUS) as a diagnosis of exclusion. Even though rare, it is paramount to diagnose TTP and aHUS associated with pregnancy and postpartum, as both require urgent specific treatment.
Link
Citation
Blood 2020; 136(19): 2103-2117
Jornal Title
Blood

Files:

NameSizeformatDescriptionLink